News · Supplements
High-dose vitamin D did not slow advanced bowel cancer
A 455-patient phase 3 trial run through the US National Clinical Trials Network added high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer. It did not delay progression.
Based on a double-blind phase 3 randomized trial in 455 patients with previously untreated metastatic colorectal cancer
- A phase 3 trial in 455 patients added high-dose vitamin D3 to standard chemotherapy.
- Time before the cancer worsened was 11.8 months against 10.3, within the play of chance.
- Survival did not differ either: 25.6 months against 27.0 on the standard dose.
- An earlier, smaller phase 2 trial had found a benefit. This larger one did not confirm it.
- The high dose caused no extra serious side effects, so this is about benefit, not harm.
Four years ago a small trial suggested that giving people with advanced bowel cancer a large daily dose of vitamin D alongside their chemotherapy bought them extra months before the disease started growing again. It was the kind of result that gets a bigger trial funded.
The bigger trial has now reported in JAMA, and the extra months did not survive it.
How the vitamin D trial was built
The earlier work was a phase 2 trial: small, designed to detect a signal worth pursuing rather than to settle anything. Its finding was that high-dose vitamin D3 added to standard treatment improved progression-free survival compared with standard-dose vitamin D3 in this cancer.
This one was built to answer the question. It was a double-blind phase 3 randomized clinical trial enrolling 455 patients with previously untreated mCRC, where mCRC is metastatic colorectal cancer, meaning bowel cancer that has already spread. It ran across the United States through the National Clinical Trials Network from October 2019 to December 2022.
Everybody got the same chemotherapy and the same additional drug. The only thing separating the two groups was the vitamin D dose: IU, or international units, is the standard measure for a vitamin dose, and the high-dose arm took 8000 IU daily for 14 days as a loading dose followed by 4000 IU daily, against 400 IU daily for the comparison group. That is roughly ten times the standard amount, sustained until the disease progressed or the patient stopped.
What high-dose vitamin D did to progression
The main measure was how long people went before their cancer started growing again.
The median was 11.8 months on the high dose, against 10.3 months for standard-dose vitamin D3. A month and a half looks like something, and it is the reason trials of this size exist: the gap did not clear the bar the trial had set for calling it real.
The other measures agreed. Measurable tumor shrinkage ran at 51% against 44%, a comparison between high-dose and standard-dose vitamin D3 that again sat inside the range chance could produce. And survival ran, if anything, the other way, at a median of 25.6 vs 27.0 months in favor of the standard dose.
Three measures, no benefit on any of them.
Whether high-dose vitamin D caused harm
It is worth being precise about what this trial did not find, because a failed treatment and a harmful one are different results.
There were no clinically meaningful differences in the most common grade 3 or greater adverse events between the groups. Serious neutropenia, a drop in the white cells that fight infection, occurred in 32% of the high-dose group against 30% of the other. Serious high blood pressure occurred in 20% against 23%. Neither is a signal.
Nor did the vitamin itself cause trouble. The trial recorded no difference in the incidence of vitamin D-associated toxicities, the raised blood calcium and kidney effects that very high doses can produce.
So this is a clean absence of benefit, not a trade-off anyone has to weigh.
Why the earlier vitamin D result did not hold
This trial is a textbook version of something that happens constantly in cancer research and almost never makes the news.
A phase 2 trial asks whether a thing is worth studying properly. It is small, and small trials swing. A result that looks convincing in a hundred patients can be an accident of who happened to be enrolled, and the only way to find out is to run it again in more people with the endpoint fixed in advance.
That is what happened here, and it is the system working rather than failing. The disappointing part is not that the phase 3 was negative. It is that the phase 2 was published, and reported, and read by people with a serious diagnosis, four years before anyone could say whether it held.
What this bowel cancer trial cannot show
The trial answers one question about one group of people, and the boundaries are worth stating plainly.
It enrolled patients with untreated metastatic colorectal cancer starting chemotherapy. It says nothing about vitamin D for anyone whose blood level is genuinely low, nothing about bone health, and nothing about whether vitamin D affects the chances of developing bowel cancer in the first place. Those are separate questions.
The trial is also paywalled, so the account here rests on its published summary rather than the authors’ full discussion of what limited it.
For anyone currently in treatment, the finding is narrow and useful: ten times the usual dose of vitamin D, taken alongside chemotherapy, did not buy more time. That is worth knowing before buying it.
People also ask
What exactly was tested?
Patients starting first-line treatment for metastatic colorectal cancer were randomly assigned to standard chemotherapy plus either high-dose vitamin D3 (8000 IU daily for 14 days as a loading dose, then 4000 IU daily) or standard-dose vitamin D3 (400 IU daily). Everyone received chemotherapy plus bevacizumab; the only difference between the groups was the vitamin D dose. Neither patients nor doctors knew which they were getting.
What did the trial find?
Median progression-free survival was 11.8 months (95% CI, 10.3-13.3) on the high dose against 10.3 months (95% CI, 9.4-12.2) on the standard dose, a gap that did not clear the trial's statistical bar (1-sided log-rank P = .25). Objective response rate was 51% versus 44% (P = .12) and median overall survival was 25.6 versus 27.0 months (P = .66).
Why did anyone expect it to work?
An earlier phase 2 randomized trial had reported that high-dose vitamin D3 added to standard treatment improved progression-free survival compared with standard-dose vitamin D3. Phase 2 trials are smaller and designed to detect a signal worth chasing, not to settle the question. Chasing it is exactly what this trial did.
Was the high dose harmful?
There was no sign of that. The trial reported no clinically meaningful differences in the most common serious side effects between the groups, including neutropenia (32% versus 30%) and hypertension (20% versus 23%), and no difference in vitamin D-associated toxicities. That matters, because it means the result is a clean absence of benefit rather than a trade-off.
Does this say anything about vitamin D for people without cancer?
No. This trial enrolled people with previously untreated metastatic colorectal cancer receiving chemotherapy, which is a specific and seriously ill population. It says nothing about correcting a deficiency, about bone health, or about prevention in healthy adults. Those are separate questions with their own evidence.
Should anyone in treatment change what they take?
This is general information, not medical advice, and supplement decisions during cancer treatment belong with an oncology team. The practical reading of this trial is narrow: taking vitamin D at ten times the standard dose alongside chemotherapy did not extend the time before the cancer progressed.
References
- Ng, K., Ou, F.-S., Zemla, T., et al. Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer. JAMA, 2026.
- National Cancer Institute. Colorectal Cancer Treatment (PDQ) - Health Professional Version. US National Institutes of Health.
- Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals. US National Institutes of Health.